2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17019
    SL-89.0591 194674-19-6 98%
    SL-89.0591 is a uroselective α1-adrenoceptor antagonist. SL-89.0591 exhibits a more potent blocking effect on urethral receptors than on vascular receptors in anesthetized rabbits, with a lower risk of orthostatic hypotension. SL-89.0591 can be used in research related to benign prostatic hyperplasia.
    SL-89.0591
  • HY-17350
    Anitrazafen 63119-27-7 98%
    Anitrazafen is a topically effective antiinflammatory agent.
    Anitrazafen
  • HY-17457
    Levalbuterol hemitartrate 661464-94-4 98.71%
    Levalbuterol (Levosalbutamol) hemitartrate is a β2-adrenergic receptor agonist and PI3K inhibitor. Levalbuterol hemitartrate inhibits PI3K activity, reduces NF-κB and Rb protein expression, activates the cAMP/PKA pathway, and stimulates cAMP release. Levalbuterol hemitartrate relaxes airway smooth muscle, reduces intracellular calcium levels, and inhibits spasmogen-induced contractions. Levalbuterol hemitartrate can be used for the research of moderate-to-severe asthma.
    Levalbuterol hemitartrate
  • HY-17479
    Amfenac 51579-82-9 98%
    Amfenac (AHR 5850) is an orally active and potent anti-inflammatory compound possessing antipyretic and analgesic properties. Amfenac can be used for the research of acute and chronic inflammation.
    Amfenac
  • HY-17481
    Bumadizone 3583-64-0 98%
    Bumadizone is a non-steroidal anti-inflammatory drug (NSAID) and can relieve pain.
    Bumadizone
  • HY-17486
    Ibuproxam 53648-05-8
    Ibuproxam (G 277) is a non-steroidal anti-inflammatory agent.
    Ibuproxam
  • HY-17487
    Miroprofen 55843-86-2 98%
    Miroprofen (Y 0213) is an orally active nonsteroidal anti-inflammatory analgesic (NSAID). Miroprofen exhibits anti-inflammatory, analgesic and anti-platelet activities.
    Miroprofen
  • HY-17491
    Proquazone 22760-18-5 98%
    Proquazone (RU 43-715) is a chemically distinctive non-steroidal anti-inflammatory agent (NSAID). unlike most other NSAIDs, Proquazone does not have a free acid group in its structure. Proquazone may inhibit or arrest progression of bone erosions. Proquazone is an orally active anti-inflammatory, analgesic and anti-pyretic agent.
    Proquazone
  • HY-17651
    PI3K-IN-60 2504036-13-7
    PI3K-IN-60 (Compound 34) is a highly selective phosphatidylinositol 3-kinase gamma (PI3Kγ) inhibitor. PI3K-IN-60 is promising for research of autoimmune diseases (e.g., multiple sclerosis) and cancers (e.g., breast cancer, pancreatic ductal adenocarcinoma).
    PI3K-IN-60
  • HY-17655
    TBE56 98%
    TBE56, a molecular glue, is a BACH1 degrader, with an EC50 of 44 nM. TBE56 is a weak NRF2 inducer and the biotinylated TBE31. TBE56 interacts and promotes the degradation of BACH1 via a mechanism involving the E3 ligase FBX022. TBE56 reduces intracellular Fe2+ accumulation, ROS generation, and malondialdehyde (MDA) content, while increasing GSH/GSSG ratio and upregulating GPX4 in Prominin-2-overexpressed BMSCs. TBE56 significantly ameliorates intervertebral disc degeneration (IVDD) in puncture-induced SD rat IVDD model. TBE56 can be used for the study of intervertebral disc degeneration (IVDD).
    TBE56
  • HY-17678
    Z-VAD-CHO 875152-90-2
    Z-VAD-CHO is a potent inhibitor of human caspase-1 with a Ki value of 0.008 μM.
    Z-VAD-CHO
  • HY-18002
    Oleanolic acid derivative 1 1724-18-1 98%
    Oleanolic acid derivative 1 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.
    Oleanolic acid derivative 1
  • HY-18003
    Oleanolic acid derivative 2 211516-63-1 98%
    Oleanolic acid derivative 2 is an oleanolic acid derivative, which is a novel triterpenoid-steroid hybrid molecule.
    Oleanolic acid derivative 2
  • HY-18228
    CP-352664 1097883-05-0 98%
    CP-352664 is a JAK inhibitor. CP-352664 has a inhibitoinhibits JAK3 with an EC50 value of 210 nM. CP-352664 is promising for research of organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.
    CP-352664
  • HY-18263
    Elubrixin hydrochloride 688763-65-7 98%
    Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
    Elubrixin hydrochloride
  • HY-18617
    rel-SB-612111 hydrochloride 371980-94-8 98%
    rel-SB-612111 hydrochloride is a novel and potent human opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). rel-SB-612111 hydrochloride exhibits selectivity for μ-, κ- and δ-receptors with Ki values of 57.6 nM, 160.5 nM and 2109 nM, respecticely. rel-SB-612111 hydrochloride effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model.
    rel-SB-612111 hydrochloride
  • HY-18618
    SB-612111 371980-98-2 98%
    SB-612111 is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 exhibits selectivity for μ-, κ- and δ-receptors with Ki values of 57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model.
    SB-612111
  • HY-18694
    CGS 27023A 169799-04-6 98%
    CGS 27023A is a non-peptidic and orally active MMP inhibitor with the Ki values of 43, 33, 20 and 8 nM for MMP-3, MMP-1, MMP-2 amd MMP-9, respectively. CGS 27023A prevents cartilage degradation in stromelysin-induced rabbit cartilage degradation model. CGS 27023A can be used for study of arthritis.
    CGS 27023A
  • HY-18709
    Tyk2-IN-3 1779493-12-7 98%
    Tyk2-IN-3 is a Tyk2 pseudokinase inhibitor, with an IC50 of 485 nM.
    Tyk2-IN-3
  • HY-18759
    BMS-751324 948842-66-8 98%
    BMS-751324 is a p38α MAPK inhibitor. BMS-751324 equips a precursor of carbamyl-methyl linkage, containing esters and phosphate functional groups derived from hydroxyphenylacetic acid (HPA). BMS-751324 effectively inhibits foot swelling and LPS-induced TNFα production in an arthritic rat model.
    BMS-751324
Cat. No. Product Name / Synonyms Application Reactivity